Beacon Harbor Wealth Advisors Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 71,133 shares of the biopharmaceutical company’s stock after purchasing an additional 1,586 shares during the period. Gilead Sciences comprises 1.7% of […]
Benjamin Edwards Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,362 shares of the biopharmaceutical company’s stock after selling 3,735 shares during the quarter. Benjamin Edwards Inc.’s holdings […]
Brighton Jones LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 9.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 12,152 shares of the biopharmaceutical company’s stock after selling 1,197 shares during the quarter. Brighton Jones LLC’s holdings in Gilead Sciences were worth $984,000 at the […]
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective reduced by equities research analysts at Maxim Group from $90.00 to $85.00 in a research note issued on Wednesday, Briefing.com reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price suggests a potential upside of 30.37% from […]
Barclays Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $76.00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences (NASDAQ:GILD – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 3.450-3.850 for the period, compared to the consensus EPS estimate of 3.670. The company issued revenue guidance of $27.1 billion-$27.5 billion, compared to the consensus revenue estimate of $25.7 billion. Gilead Sciences also updated […]
Gilead Sciences (NASDAQ:GILD – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 3.450-3.850 for the period, compared to the consensus EPS estimate of 3.670. The company issued revenue guidance of $27.1 billion-$27.5 billion, compared to the consensus revenue estimate of $25.7 billion. […]
Gilead Sciences, Inc. (NASDAQ:GILD) Declares $0.77 Quarterly Dividend theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Bahl & Gaynor Inc. decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,390 shares of the biopharmaceutical company’s stock after selling 1,155 shares during the quarter. Bahl & Gaynor Inc.’s […]
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) announced a quarterly dividend on Thursday, April 25th, Zacks reports. Stockholders of record on Friday, June 14th will be paid a dividend of 0.77 per share by the biopharmaceutical company on Thursday, June 27th. This represents a $3.08 dividend on an annualized basis and a dividend yield […]